id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9039 R30842 |
Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.83 [0.05;13.63] C excluded (control group) |
1/4 2/7 | 3 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9040 R30852 |
Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 3.33 [0.23;49.10] C | 1/4 2/22 | 3 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9042 R30869 |
Bank (Oxcarbazepine) (Mixed indications), 2017 | Admission to neonatal intensive care unit (NICU) or Special Care Nursery | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.65 [0.03;14.14] C | 0/4 6/36 | 6 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9036 R30803 |
Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.59 [0.35;1.01] C excluded (control group) |
46/465 24/154 | 70 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9037 R30815 |
Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.33 [0.98;1.82] excluded (control group) |
46/465 49,612/689,482 | 49,658 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9038 R30827 |
Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.04 [0.73;1.49] | 46/465 152/1,708 | 198 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9064 R30943 |
Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 | Admission to a neonatal unit | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 37.81 [1.54;928.50] C | 2/2 1,822/24,778 | 1,824 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 2.02 [0.48;8.47] | 2,031 | 475 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Mixed indications; 3: Oxcarbazepine) (Controls unexposed, sick; 4: Oxcarbazepine) (Controls unexposed, disease free) ;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9036, 9037, 9039